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Katherin Eliza Leckie 
CONTEMPORARY OUTCOMES OF DISTAL LOWER EXTREMITY BYPASS FOR 
CHRONIC LIMB THREATENING ISCHEMIA AND A MODEL BASED 
COMPARISON WITH NON-SURGICAL THERAPIES 
Objective: Gold standard therapy for chronic limb threatening ischemia (CLTI) is 
revascularization but in patients in whom below-the-knee bypass is indicated autologous 
vein conduit may not be available. Contemporary outcomes of distal bypass with 
suboptimal conduits have not been well described and recent advances in non-surgical 
therapies raise the question of whether in some cases there is evidence that these should 
be considered. 
Methods: Data was obtained from the Vascular Quality Initiative (VQI) registry 
as well as from a multi-center, randomized clinical trial of cell therapy. Incidence of 
major amputation after distal bypass was estimated for the VQI cohort by conduit type 
using non-parametric survival analysis with death as a competing risk. A cox 
proportional hazards model was then fit to the pooled data in a stepwise fashion with 
death as a competing risk, including evaluations for appropriate transformation, time 
dependency and interactions for each included covariate, and hazard ratios were 
estimated for the risk of major amputation by treatment.   
Results: At 365 days, the estimated cumulative incidence of major amputation 
with death as a competing risk is 25% after distal bypass with non-autologous biologic 
conduit (0.2499, 95% CI 0.2242 - 0.2785), 13% for prosthetic (0.1276, 95% CI 0.1172 - 
0.1389) and 9% for GSV (0.0900, 95% CI 0.0848 - 0.0956). The cox proportional 
hazards model found a significant interaction between age and treatment. Compared to 
vi 
bypass with non-autogenous biologic, the hazard ratios for bypass with GSV were 0.41 
(p<0.0001), 0.41 (p<0.0001), 0.42 (p<0.0001) and 0.42 (p<0.0001) respectively at ages 
55, 60, 65 and 70 and for bypass with prosthetic were 0.68 (p=0.0043), 0.67 (p=0.0004), 
0.65 (p<0.0001) and 0.64 (p<0.0001) respectively and for autologous cell therapy 0.22 
(p=0.0005), 0.34 (p=0.0011), 0.52 (p=0.0196) and 0.76 (p=0.3677) respectively. No 
significant differences were found between best medical management and distal bypass 
with non-autologous biologic. 
Conclusion: The risk of major amputation after distal bypass is lowest in patients 
with GSV conduit and highest following bypass with non-autologous biologic. Using a 
semi-parametric model, cell therapy was estimated to significantly decrease the risk of 
amputation compared to distal bypass with non-autologous biologic conduit in younger 
patients.  
Giorgos Bakoyannis, Ph.D., Chair 
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Peripheral vascular disease (PVD) can manifest as intermittent claudication (IC) 
or chronic limb threatening ischemia (CLTI). CLTI has a prevalence of 1.3%1,2 and an 
estimated incidence of 500-1000/million per year1 and carries with it a high risk of 
amputation and mortality even with revascularization2-5 and higher when there are no 
revascularization options.3,6 Restoration of blood flow is the gold standard of treatment, 
either by open surgical reconstruction or an endovascular intervention. Open 
reconstruction with autologous great saphenous vein (GSV) has good long term results 
with 5 year amputation free survival reported >50% and limb salvage rates and 
approaching 90%.5,7 Autologous conduit is not always available however and up to 30% 
of patients who would be candidates for surgical bypass do not have adequate vein.7,8 
Alternative conduits include allografts (cryopreserved arteries, umbilical-cord veins, 
cryopreserved veins) and prosthetic grafts (polytetrafluoroethylene (PTFE) and polyester 
(Dacron(R)).  
These are all considered inferior to autologous vein in distal bypasses (distal 
anastomosis below the knee) with less than 25% patency for allografts9 and less than 50% 
patency at five years for prosthetic10,11, although it is suggested the patency of PTFE 
bypasses may be improved with use of a vein cuff12 or heparin bonded PTFE.13,14 Even 
with improved patency, however, PTFE is inferior to autologous vein with respect to 
limb salvage, 60% vs 90% at 5 years.5,7,14,15  
But not all patients undergo reconstruction; between 20% and 40% of new cases 
of CLTI will have no options or not be candidates for revascularization. The morbidity 
and mortality of medically managed CLTI is significant but has decreased over the last 
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couple of decades with estimated one year mortality of 22% and major amputation rate 
also around 22%.6,16 This is especially interesting because in a recent retrospective 
review of open reconstruction with alternative conduits in 240 patients, freedom from 
major adverse limb events or death at one year was just 60%17 which is comparable to 
medically managed CLTI. While non-interventional therapy for CLTI patients primarily 
consists of optimal medical management of comorbidities and wound care, other 
potential non-surgical treatments under investigation for no option CLTI patients include 
intramuscular injections of autologous bone marrow derived cells (BMCs). Since the 
early 2000s there have been multiple small randomized clinical trials investigating the 
efficacy of BMCs and meta-analyses provide evidence that cell therapy may decrease 
major amputation by 40% 18,19. 
The MOBILE trial was a multi-center, double-blind, randomized, placebo-
controlled trial conducted at 26 centers in the U.S. evaluating the efficacy intramuscular 
injections autologous bone marrow cells in patient’s presenting with Rutherford 4 or 5 
critical limb ischemia who had no surgical options or were not considered surgical 
candidates.20 152 patients (155 limbs) were enrolled and randomized 3:1 to concentrated 
bone marrow nucleated cells (cBMNC) or placebo respectively. Randomization was 
stratified by investigative site as well as by diabetic status and Rutherford category. The 
primary endpoint was amputation-free survival (AFS), a composite measure of major 
amputation of the index limb and all-cause death, at 52 weeks after treatment. The 
secondary endpoints included major amputation, death, and minor amputation as well as 
changes from baseline in measures of limb perfusion, ambulation and quality of life. 
While one year results failed to reach significance, (AFS 80% vs. 70%, p=0.224), the two 
3 
year results, as presented at the 2019 Vascular Annual Meeting, were notable for a 
significant improvement associated with cell therapy with AFS of 77% compared to 56% 
in the control group (p=0.028). The 70% freedom from events seen in the control group 
at 1 year again highlights the issue of improved contemporary outcomes in medically 
managed CLTI and the associated loss of statistical significance in studies powered for a 
higher baseline event rate. 
These promising results of cell-based therapy, combined with the observation that 
the natural history of untreated CLTI has improved over the last few decades 6 and that 
outcomes following surgical bypass with alternative conduits are poor 17 raises the 
question of whether the target population of CLTI patients for whom cell therapy might 
be considered could and should be expanded to those who are receiving sub-optimal 
reconstruction. This question is difficult to approach in the existing literature because of 
the heterogeneity of this patient population and the differing inclusion and exclusion 
criteria across randomized trials and observational studies (the former being stricter and 
therefore having healthier patients while the later tend to be cross sections of the 
population).  
The goals of this project was to analyze de-identified patient data from a national 
prospectively maintained database who had distal bypass to describe contemporary 
outcomes of distal bypass with alternative conduit. Next, a pooled dataset including the 
de-identified patient data from the MOBILE trial was used to compare outcomes 
following cell therapy or medical management only with the surgical reconstruction 
cohort by fitting an appropriate semi-parametric survival model to adjust for differences 




The Vascular Quality Initiative (VQI) collects demographic, clinical, procedural 
and outcomes data on selected commonly performed vascular procedures in participating 
institutions across the USA and Canada. These procedures include carotid 
endarterectomy (CEA), carotid artery stenting (CAS), infrainguinal and suprainguinal 
bypass, open infrarenal abdominal aortic aneurysm (AAA) repair, endovascular 
infrarenal AAA repair (EVAR), thoracic endovascular aortic repair, including branch and 
fenestrated AAA repair, peripheral vascular intervention of aortoiliac and lower 
extremity arterial disease, and hemodialysis access. The selection of the variables 
collected at each site and for each procedure was motivated by the goal of ensuring 
enough patient information and procedural details for risk-adjustment and process 
analysis as well as key outcome information. Participating locations agree to collect all 
the specified variables as well as contact the patients for at least a 1 year follow up. The 
primary purpose of the VQI is to provide data and analyses to the participating centers for 
internal quality initiatives in accordance to the Patient Safety Act. But aggregate de-
identified data is also made available for research projects as approved the Society for 
Vascular Surgery (SVS) Patient Safety Organization (PSO) Quality Committee.21  
For this analysis, data from the Infra-Inguinal Bypass registry was requested and 
obtained from the SVS PSO. This dataset included patients who had a lower extremity 
bypass between 2009 and 2019. Procedures are assigned unique ID numbers upon entry 
into the database and this was used to unite de-identified follow up data with the 
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procedural and demographic information obtained from the index procedure entry. 
Unique center IDs were used for clustering. 
Patients with non-missing amputation status at any follow up time after their 
primary procedure were isolated. Major amputation was defined as either below knee 
(BKA) or above knee (AKA) or unspecified major amputation (retired terminology). 
Time of event was recorded as days between index procedure and major amputation. 
Patients who never underwent an amputation were censored on the last recorded long-
term follow up contact at which amputation status was assessed or on death if this 
occurred before or within 30 days of last recorded long-term follow up contact. If the 
patient died within this follow up window, death was coded as a competing event. In 
those cases where survival was assessed using the Social Security Death Index (SSDI) 
death might be recorded significantly later than the time of last contact with the patient. 
So in the case of death greater than 30 days after the last recorded follow up then they 
were censored at the time of contact. For example, a patient who was contacted at 202 
days after surgery and had not undergone amputation at that time but is noted to have 
died 372 days after their index surgery is censored without event at 202 days because 
their amputation status in the intervening 170 days is unknown. Additionally, as all 
participating centers attempt to obtain follow up data on patients in the registry within a 
9-21 month window from the index procedure to comply with the 1 year follow up 
requirement but only some continue to collect patient data over a longer timeframe, for 
the purposes of this analysis all patients are censored after the common follow up period 
at 640 days or approximately 21 months.  
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The patient population of interest was then identified as those with a below knee 
bypass, defined as a recipient vessel at or distal to the below knee popliteal artery but 
proximal to the foot (i.e. tarsal or plantar bypasses were excluded), with any of GSV, 
prosthetic or biologic (non-autologous artery or vein) grafts. Non-GSV autologous vein 
grafts and composite grafts were excluded. Patients with bypass for aneurysmal 
pathology or acute ischemia were excluded.  
Potential predictor variables included demographics as well as risk factors and 
comorbidities. The included age at time of surgery in years, gender as birth sex, race as a 
factor consisting of black, white (non-Hispanic) and other and body mass index (BMI). 
Medication use history included pre-operative use of aspirin, P2Y12-receptor blocker, 
angiotensin-converting enzyme inhibitor (ACE-I), beta-blocker, statin or anticoagulant. 
Medical history included smoking status as current, prior or never, diabetes as none, diet-
controlled/oral agents only or insulin dependent and chronic obstructive pulmonary 
disease (COPD) as none, medication controlled or oxygen dependent. Coronary artery 
disease (CAD), congestive heart failure (CHF), dialysis, prior bypass and prior 
percutaneous interventions were included present or not. Perioperative factors included 
ischemia as no chronic-limb-threatening ischemia, rest pain or tissue loss, ambulatory 
status as either ambulatory (with or without assistance) or non-ambulatory (wheelchair or 
bedridden), preoperative serum creatinine, hemoglobin, ankle brachial index (ABI) and 
toe brachial index (TBI). 
Statistical Analysis of VQI data 
The first aim of this analysis was to evaluate contemporary outcomes of distal 
bypass by conduit. A descriptive comparison of the potential predictor variables was 
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made across the three types of conduit, biologic (non-autologous), prosthetic and GSV 
and means or percentages were reported as appropriate. One-way analysis of variance 
(ANOVA) was used for continuous variables and chi-square tests for factors.  
Non-parametric estimates of the probability of major amputation, the outcome of 
interest, were then obtained. Given that patients may die without having experienced an 
amputation, death was treated as a competing risk for this analysis and the population-
averaged cumulative incidence function was estimated using the nonparametric working-
independence version of the Aalen-Johansen estimator.22 Cumulative incidence estimates 
were stratified by conduit across the entire cohort. Center ID was used to group 
observations for robust variance estimation using an infinitesimal jackknife approach. 
Additional stratification by select potential predictors of major amputations is 
serially performed for the cohort that received a distal bypass with prosthetic conduit as 
this patient group may represent a point of clinical equipoise for many practitioners.  
Predictors considered include diabetes, smoking status, race and degree of ischemia on 
presentation, target vessel, end-stage renal disease, ambulatory status and history of lower 
extremity bypass. Pairwise equality between groups within each stratum was tested as 
proposed by Gray (1988).23 The Bonferroni method was used to correct for multiple 
comparisons. Probability of amputation with death as a competing risk was estimated at 1 
year for all strata. Confidence intervals calculated using robust variance estimates to 
account for the within-center dependence. 
Statistical Analysis of pooled data 
The second aim of this analysis was to compare outcomes of distal bypass with 
any of the three conduit types with best medical management or autologous cell therapy 
8 
and to this end a subset of the VQI data was pooled with de-identified data from the 
MOBILE trial. Patients in the VQI dataset with severe congestive heart failure or on 
dialysis were not included as these were exclusion criteria for the MOBILE trial. A 
comparison of potential predictor variables was made between the two patient sources 
and means or percentages were reported as appropriate. T-tests were used for continuous 
variables and chi-square tests for factors.  
Cause-specific hazard of major amputation was then modeled using a 
semiparametric Cox proportional hazard model and censoring death. Center ID was used 
to group observations for robust variance estimation using an infinitesimal jackknife 
approach in order to account for the within-center dependence. A base model was fit 
using treatment (five levels for bypass with GSV, prosthetic or non-autogenous biologic, 
medical management only or cell therapy). Candidate predictors (listed previously) were 
screened for inclusion in further model selection by conducting a likelihood-ratio chi-
square test for the addition of each to the base model. A significance level threshold of 
0.2 was used. Variables with greater than 10% missing values were excluded. 
Logarithmic and exponential transformations of continuous variables were considered at 
this stage as candidates for inclusion. 
Identified predictors were then included in a stepwise model selection procedure 
using Akaike information criterion (AIC). Type III analysis of variance tests (likelihood 
ratio (LR)) are conducted on the variables included in the last iteration and only those 
with p-value less than 0.05 are left in the model. 
The resulting model was evaluated for violations of the proportional hazards 
assumption by plotting the scaled Schoenfeld residuals against transformed time and 
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testing for correlation.24 Variables with indication of correlation (p-value < 0.05) were 
evaluated for a significant time interaction. This was fit by splitting each patient 
observation into 30 day intervals and adding an interaction term between the variable 
violating the proportional hazards assumption and the start time of the interval. Both 
linear, logarithmic and exponential transformations of start time were considered. 
Additionally, a model was considered that allowed piecewise proportional hazards with 
constant coefficients between 0 and 90 days (early), 90 and 365 days (medium) and after 
365 days (late). Models were compared by AIC. 
Type II analysis of variance tests (Wald) are conducted on time interactions and 
only those with p-value less than 0.05 remain in the model. Two-way interactions 
between all main effects included in the model at this stage were then screened for 
inclusion in further model selection by conducting a likelihood-ratio chi-square test for 
the addition of each to the base model. A significance level threshold of 0.2 was used to 
select interaction terms to include in a forwards selection procedure using AIC. Type II 
analysis of variance tests (Wald) are conducted on the interaction terms included in the 
last iteration and only those with p-value less than 0.05 remain in the final model. 
A forest plot for the hazard ratios with 95% confidence intervals associated with 
the levels of treatment is generated for this final model with Biologic graft as the 
reference level. Similar representations of the hazard ratios associated with diabetes, 
smoking status, race and degree of ischemia on presentation are also constructed. In the 
case of time dependency, the hazard ratios are calculated for 1 year. In the case of any 





Patient entries from the VQI Infra-Inguinal Bypass registry were united using the 
unique primary procedure identification number. 43,168 unique procedures were 
identified and those with missing conduit type, indication for surgery or amputation 
status on follow up were excluded. 31,591 (73.2%) were found with this minimum 
complete follow up and this cohort was then narrowed to those with below the knee 
bypass with either GSV, prosthetic or non-autologous biologic conduits. Composite and 
non-GSV autologous vein grafts, tarsal and pedal bypass targets and procedures 
performed for aneurysmal disease or acute ischemia were excluded. This final distal 
bypass cohort including 17,111 unique procedures. (Figure 1) 
 
Figure 1: Diagram of patient selection from VQI Infra-Inguinal Bypass registry. 
*excluding patients with missing indication for surgery, conduit type or amputation 
status 







17,111 with distal 




Descriptive statistics and non-parametric survival analysis in the VQI cohort 
A comparison of the potential predictor variables was made across the three types 
of conduit: biologic (non-autologous), GSV and prosthetic. These are presented in Table 
1. The percent missing entries for each covariate is reported as well as the p-value for a 
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0.04% < 0.0001 
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6.23% < 0.0001 
Pre-op ABI 0.56 (726) 0.52 (2994) 0.58 (9106) 25.05% < 0.0001 







0.53% < 0.0001 
Table 1: Distribution of potential predictor variables by conduit type. Reported p-values 
are for a chi-square test or ANOVA for the categorical and continuous predictors 
respectively 
 
As we would suspect, there are multiple significant differences in the distribution 
of demographic, medical and perioperative factors between the three conduit types. In 
general, patients who had a bypass with GSV appear to be younger, more likely male, 
more likely to be currently smoking but with fewer comorbidities and prior procedures. 
Among the evaluated comorbidities, only in end-stage renal disease (ESRD) and insulin 
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dependent diabetes (IDDM) is there a lower percentage of patients in the cohort that 
underwent prosthetic bypass compared to the GSV cohort. 
Because of this unbalanced distribution of potential risk factors, a comparison in 
outcomes between conduit types will necessarily reflect the contribution of those risk 
factors as well as the graft type. Such a comparison is still of value however, as this 
national, prospectively-collected database likely reflects actual practice patterns. 
To obtain non-parametric estimates of the probability of major amputation, death 
was treated as a competing risk and marginal probability estimates using a cumulative 
incidence function were employed. Cumulative incidence estimates were stratified by 
conduit across the entire cohort. (Figure 2) 
 
 
Figure 2: Population-averaged cumulative incidence of major amputation after distal 
bypass by conduit. Dashed vertical line at 365 days. 
 
Pairwise, these curves are statistically significantly different by Gray’s test with a 
p-values < 0.0001. At 365 days, the estimated population-averaged probability of major 
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amputation with death as a competing risk is 25% after distal bypass with non-autologous 
biologic conduit (0.2499, 95% CI 0.2242 - 0.2785), 13% for prosthetic (0.1276, 95% CI 
0.1172 - 0.1389) and 9% for GSV (0.0900, 95% CI 0.0848 - 0.0956). 
Additional stratification by potential predictors of major amputations is performed 
for the 3,982 patients that received a distal bypass with prosthetic conduit as this patient 
group may represent a point of clinical equipoise for many practitioners.  
 
Figure 3: Population-averaged cumulative incidence of major amputation after  
distal bypass with prosthetic graft by covariates - part 1. Stratified by diabetes (A), 
smoking status (B), race (C) and degree of ischemia (D). Dashed vertical line at 365 days. 
 
In figure 3, the cumulative incidence of major amputation after distal bypass with 
prosthetic conduit is plotted by diabetic status, smoking status, race and degree of 
ischemia. At 365 days, the estimated marginal probability of major amputation with death 
as a competing risk is 12% for non-diabetics (0.1178, 95% CI 0.1037 - 0.1339), 11% in 
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those with diet-controlled diabetes or on oral medications only (0.1123, 95% CI 0.0931 - 
0.1356) and 16% for patients on insulin (0.1579, 95% CI 0.1369 - 0.1823). 
The corrected α-level for 3 pairwise comparisons using the Bonferroni method is 
0.0167. 
Pairwise by Gray’s test, the insulin-dependent diabetics are significantly different 
than both the non-diabetics (p = 0.0025 < 0.0167) and the diabetics on diet or oral 
therapy (p = 0.0049 < 0.0167) but there is no significant difference between the non-
diabetic and diet/oral medication controlled cohorts (p = 0.7270 > 0.0167). 
By smoking status at time of the index surgery, the estimated probability of major 
amputation at 1 year is 12% for never-smokers (0.1237, 95% CI 0.0975 - 0.1569), 11% 
for previous smokers (0.108, 95% CI 0.0947 - 0.1232) and 16% for current smokers 
(0.1566, 95% CI 0.1381 - 0.1775). Pairwise by Gray’s test, the current smokers are 
significantly different compared the prior smokers (p < 0.0001 < 0.0167) but there is no 
significant difference between current and never smokers using the Bonferroni corrected 
α-level (p = 0.0394 > 0.0167) or between the prior and never smokers (p = 0.4956 > 
0.0167). 
Stratified by race, the risk of major amputation is estimated at 19% in black 
patients (0.1926, 95% CI 0.1647 - 0.2253), 11% in whites (0.11, 95% CI 0.099 - 0.1222) 
and 19% in other races (0.1897, 95% CI 0.1358 - 0.2648).  Pairwise by Gray’s test, the 
white cohort is significantly different than both the black cohort (p < 0.0001 < 0.0167) 
and the other cohort (p = 0.0114 < 0.0167) but there is no significant difference between 
the black cohort and other races (p = 0.0955 > 0.0167). 
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By ischemic status of the index limb at time of surgery, the probability of 
amputation at 1 year is 5% for those without CLTI (0.0525, 95% CI 0.0403 - 0.0685), 
14% in those with rest pain (0.1449, 95% CI 0.1262 - 0.1664) and 16% if the patient 
presented with tissue loss (0.1645, 95% CI 0.1465 - 0.1847). Pairwise by Gray’s test, the 
cohort without CLTI is significantly different than both the rest pain (p < 0.0001 < 
0.0167) and the tissue loss groups (p < 0.0001 < 0.0167) but the separation between the 
rest pain and tissue loss cohorts did not reach significance (p = 0.0529 > 0.0167). 
Figure 4: Population-averaged cumulative incidence of major amputation after  
distal bypass with prosthetic graft by covariates - part 2. Stratified by target vessel (A), 
end-stage renal disease (B), ambulatory status (C) and history of lower extremity bypass 
(D). Dashed vertical line at 365 days. 
 
In figure 4, the cumulative incidence of major amputation after distal bypass with 
prosthetic conduit is plotted by target outflow vessel, end-stage renal disease, ambulatory 
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status and history of lower extremity bypass. At 365 days, the estimated marginal 
probability of major amputation is 8% if the outflow was the below-knee popliteal artery 
(0.0842, 95% CI 0.0735 - 0.0965), 13% if the target was the tibioperoneal trunk (0.1341, 
95% CI 0.0968 - 0.1858) and 22% if the outflow was one of the tibial vessels (0.2169, 
95% CI 0.1939 - 0.2425). Pairwise by Gray’s test, the below-knee popliteal target is 
significantly different from both the bypasses targeted to the tibioperoneal trunk (p = 
0.0015 < 0.0167) or the tibial vessels (p < 0.0001 < 0.0167) and there is also a significant 
difference between the tibioperoneal trunk and the tibial vessels as outflow target (p = 
0.0106 < 0.0167). 
For the final three strata, there are just two groups being compared so the 
Bonferroni correction was no longer necessary. For patients on dialysis the likelihood of 
major amputation at 1 year is 19% (0.1872, 95% CI 0.1369 - 0.256) compared to 12% in 
the absence of renal failure (0.1246, 95% CI 0.1141 - 0.1361) and this difference is 
statistically significant with a p-value of 0.0111.  Stratified by ambulatory status prior to 
index surgery, the risk of major amputation is estimated at 12% if the patients is 
ambulatory (0.1209, 95% CI 0.1105 - 0.1322) and 26% if the patient is non-ambulatory 
(0.2594, 95% CI 0.2006 - 0.3353) and these are groups are significantly different with a 
p-value < 0.0001. In patients with a history of lower extremity bypass, the probability of 
amputation at 1 year is 16% (0.1594, 95% CI 0.1425 - 0.1783) compared to 10% in those 
without prior bypass (0.1018, 95% CI 0.0895 - 0.1159). These groups are significantly 
different with a p-value of < 0.0001. 
Overall, these non-parametric estimations of incidence of major amputation in the 
prosthetic cohort reveal expected associations between known risk factors and 
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amputation, including worse outcomes with insulin dependent diabetes, current smoking 
status, non-white race, presence of CLTI, ESRD and non-ambulatory status and prior 
revascularization surgery. Interestingly however, there is no significant difference 
between non-diabetics and those with diet/oral medication controlled diabetes. Also, 
there appears to be an increased early risk in non-smokers which is very similar to current 
smokers but the curves separate after ~150 days so that ultimately the 1 year risk in non-
smokers is more similar prior smokers. While this observation invites speculation, in this 
non-randomized patient cohort there is expected to be unequal distribution of other risk 
factors across the strata so interpretation should be undertaken with care. 
Descriptive statistics and semi-parametric survival analysis in the pooled cohort 
Next a subset of the VQI data was pooled with de-identified data from the 
MOBILE trial and a comparison of the potential predictor variables was made across the 
two patient sources: VQI and MOBILE. These are presented in Table 2. The percent 
missing entries for each covariate is reported as well as the p-value for a chi-square test 








Gender   0.02% 0.016 
Female 41.29% (64) 31.89% (5120)   
Smoking status   0.06% < 0.0001 
Never 21.29% (33) 15.76% (2529)   
Prior 61.94% (96) 44.74% (7179)   
Current 16.77% (26) 39.5% (6339)   
HTN   0% 1 
Yes 88.39% (137) 88.51% 
(14211) 
  
Prior Bypass   0.01% < 0.0001 




  0.05% < 0.0001 
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Yes 70.97% (110) 45.55% (7310)   
CAD   0.05% 0.7518 
Yes 31.61% (49) 30.12% (4833)   
COPD   0.04% 0.4708 





25.81% (40) 22.82% (3663)   
Yes, on oxygen 0.65% (1) 1.73% (278)   
Preop aspirin   0.04% 0.2542 





  0.08% 0.0569 
Yes 38.06% (59) 30.65% (4917)   
Preop statin   0.04% 0.0201 





  0.1% 0.9369 
Yes 58.71% (91) 59.35% (9519)   
Preop ACE-I   18.59% 0.5179 
Yes 50.97% (79) 53.9% (7030)   
Preop 
Anticoagulation 
  18.63% < 0.0001 
Yes 48.39% (75) 17.93% (2337)   
Race   0.01% 0.3115 
Black 18.06% (28) 15% (2409)   
White 76.13% (118) 80.81% 
(12974) 
  
Other 5.81% (9) 4.19% (672)   
Ambulatory   0.33% < 0.0001 
Yes 84.67% (127) 95.28% 
(15252) 
  
CHF   0% 0.3268 
Yes 11.61% (18) 14.74% (2367)   
Diabetes   0.01% 0.0202 
No 59.35% (92) 48.62% (7806)   
Yes (diet or 
oral meds) 
16.13% (25) 23.48% (3770)   
Yes (on insulin) 24.52% (38) 27.9% (4479)   
Ischemia   0% < 0.0001 
No CLTI 0% (0) 25.19% (4045)   
Rest Pain 56.77% (88) 28.62% (4596)   
Tissue Loss 43.23% (67) 46.18% (7415)   
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Elective   0.02% < 0.0001 












Age (years) 64.93 (155) 66.94 (16050) 0.04% 0.02105 
Creatinine 
(mg/dl) 
1.05 (155) 1.09 (15958) 0.6% 0.18066 
Hemoglobin 
(g/dl) 
12.91 (155) 12.41 (15080) 6.02% 0.0004 
Pre-op ABI 0.47 (136) 0.55 (12140) 24.27% 0.00394 
Pre-op TBI 0.19 (89) 0.25 (4801) 69.84% 0.00358 
BMI 28.31 (154) 27.64 (15975) 0.51% 0.16137 
Table 2: Distribution of potential predictor variables by patient source. Reported p-values 
are for a chi-square or t-test for the categorical and continuous predictors respectively. 
 
Unsurprisingly, there are multiple significant differences in the distribution of 
demographic, medical and perioperative factors between the VQI and MOBILE data. 
Notably, patients who participated in the clinical trial had a significantly higher incidence 
of previous bypass and percutaneous interventions. The mean pre-procedural ABI or TBI 
was also lower in the MOBILE patients and they were less likely to be current smokers or 
diabetic and more likely to be female or on anticoagulation.  
This unbalanced distribution of potential risk factors cannot but highlight that 
even with an appropriate model to control for significant predictors of major amputation 
in the absence of randomization it is impossible to guarantee that all biases have been 
accounted for. Nevertheless, a model still provides a mechanism to control for the effects 
of many covariates and thus will allow an initial comparison of outcomes of distal bypass 
in the VQI data set with best medical management or autologous cell therapy in the 
MOBILE data set. For this purpose, cause-specific hazard of major amputation was 
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estimated from the pooled data using a Cox proportional hazard model and right-
censoring death.  
Model fitting was performed as described above. Preoperative ACE-I and 
anticoagulation, ABI and TBI were excluded for missing greater than 10% of entries. 
Categorical main effects included in the final model were treatment, degree of ischemia 
on presentation, history of lower extremity bypass, ambulatory status prior to index 
procedure, whether the procedure was elective, diabetic status, preoperative smoking 
status, diagnosis of CHF and preoperative aspirin use. Continuous main effects included 
BMI and log transformations of age, preoperative hemoglobin and preoperative serum 
creatinine respectively. A significant time interaction (i.e. correction for violation of 
proportional hazards assumption) was found for preoperative smoking status, 
preoperative aspirin use, degree of ischemia on presentation, whether the index procedure 
was elective and for BMI.  
This time dependence was modeled by splitting each patient observation into 30 
day intervals and fitting an interaction between the main effect and a log transformation 
of the start time of each interval. This log transformation resulted in the best fit by AIC 
compared to linear or exponential transformation and compared to the piecewise 
proportional hazards model. The final model had no significant violation of proportional 
hazards with all p-values > 0.05. A number of significant interactions between main 
effects were found and are listed in table 3. 
Main effect: Interaction with: P-value 
Treatment Log Age =0.0407 
Ischemia Log Time =0.0006 
 Elective =0.0019 
Race Ambulatory =0.0013 
Log Age Treatment =0.0407 
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 Smoking =0.0234 
 CHF =0.0312 
Log Hemoglobin Prior Bypass =0.0332 
Prior Bypass BMI =0.0028 
 Log Hemoglobin =0.0332 
Ambulatory Race =0.0013 
Elective Log Time =0.0047 
 Ischemia =0.0019 
 Diabetes =0.0118 
BMI Log Time =0.0132 
 Prior Bypass =0.0028 
Diabetes Smoking =0.0009 
 Elective =0.0118 
Log Creatinine   
Smoking Log Time =0.0213 
 Diabetes =0.0009 
 Log Age =0.0234 
CHF Log Age =0.0312 
Preop Aspirin Log Time =0.0079 
Table 3: Main effects included in the final model with their respective significant 
interactions. P-value is provided for the Type II chi-square test (Wald) for inclusion of 
interaction term in the model. 
 
In the presence of significant interactions, main effects can only be interpreted in 
the context of those interaction. Treatment was found to have a significant interaction 
with log transformed age. In figure 5, the hazard ratios of major amputation for each 
treatment group are estimated at ages 55, 60, 65 and 70 with non-autologous biologic 
conduit as the reference level. (Bypass with non-autologous biologic conduit was selected 
as the reference level rather than best medical management as the small sample size in 
the latter group from the MOBILE trial and the associated large standard error resulted in 
few meaningful comparisons.) Both distal bypass with GSV and bypass with prosthetic 
significantly decrease the risk of major amputation across all ages compared to bypass 
with non-autologous biologic conduit (Figure 5).  Estimated hazard ratios for bypass with 
GSV at ages 55, 60, 65 and 70 compared with bypass with biologic were 0.41 (95% CI 
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0.32 - 0.52), 0.41 (95% 0.33 - 0.51), 0.42 (95% 0.34 - 0.51) and 0.42 (95% 0.34 - 0.52) 
respectively and analogously for bypass with prosthetic were 0.68 (95% CI 0.53 - 0.89), 
0.67 (95% CI 0.53 - 0.83), 0.65 (95% CI 0.53 - 0.80) and 0.64 (95% CI 0.52 - 0.79) 
respectively. GSV is also superior to prosthetic across all ages (hazard ratios of 0.60, 
0.62, 0.64 and 0.66 respectively, p-values < 0.0001, see Appendix A for figure). These 
show little evidence of significant interaction with age however this is notable in the 
change in the hazard ratio of major amputation for the MarrowStim (autologous cell 
therapy) group with increasing age. In younger patients there is a significantly decreased 
risk of amputation in the cell therapy group compared to bypass with non-autologous 
biologics with estimated hazard ratios of major amputation of 0.22 (95% CI 0.09 - 0.51), 
0.34 (95% CI 0.18 - 0.65) and 0.52 (95% CI 0.30 - 0.90) at ages 55, 60 and 65 
respectively (Figure 5) and at 55 and 60 years this decreased risk is also significant 
compared to bypass with prosthetic conduit with hazard ratios of major amputation of 
0.32 (95% CI 0.14 - 0.73) and 0.51 (95% CI  0.28 - 0.95) respectively (see Appendix A 
for figure). By age 70 however, the cell therapy group is no longer significantly different 
than biologic bypass with a hazard ratio of 0.76 (0.42 - 1.38). 
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Figure 5: Hazard ratio of major amputation and 95% confidence interval for each 
treatment group compared to biologic bypass and adjusted for age.  
Analogously, hazard ratios for major amputation were calculated for diabetes, 
smoking status, race and degree of ischemia and these estimates were stratified by the 
respective covariates with which there were significant interactions. Diabetes was found 
to have a significant interaction with preoperative smoking status and whether the 
procedure was elective. Hazard ratios for major amputation by diagnosis of diabetes were 
stratified by smoking history and were estimated for elective patients (elective rather than 
urgent/emergent as the former represented 82% of the cohort) and are presented in figure 
6. In never smokers, a diagnosis of either level of diabetes is associated with an increased 
risk of major amputation; hazard ratio of 1.92 (95% CI 1.43 - 2.58) in insulin-dependent 
1.23 (0.50 - 3.04),  p=0.6534
0.41 (0.32 - 0.52),  p<0.0001
0.22 (0.09 - 0.51),  p=0.0005







1.17 (0.57 - 2.37),  p=0.6722
0.41 (0.33 - 0.51),  p<0.0001
0.34 (0.18 - 0.65),  p=0.0011







1.11 (0.57 - 2.16),  p=0.7630
0.42 (0.34 - 0.51),  p<0.0001
0.52 (0.30 - 0.90),  p=0.0196







1.06 (0.49 - 2.29),  p=0.8866
0.42 (0.34 - 0.52),  p<0.0001
0.76 (0.42 - 1.38),  p=0.3677
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diabetes and 1.53 (95% CI 1.07 - 2.18) in diabetics on diet or oral medications compared 
to non-diabetic patients. However, in those patients who were previous smokers while 
insulin-dependent diabetes is still a significant risk factor (HR 1.65, CI 1.34 - 2.02, 
p<0.0001) diabetes that is controlled with diet or oral medications is no longer associated 
with increased risk of major amputation (HR 0.96, CI 0.74 - 1.24, p=0.7611) and in 
current smokers there is no significant increase in risk of major amputation with either 
level of diabetes: hazard ratios of 0.86 (95% CI 0.70 - 1.05,  p=0.1275) and 1.13 (95% CI 
0.94 - 1.36,  p=0.1816) for diet/oral medication controlled diabetics and insulin 
dependent diabetics respectively. A naive interpretation might be that this indicates that 
smoking has a protective or mitigating effect on diabetes but when we consider that 
smoking is also a significant risk factor for major amputation (figure 7), we suggest that 
this effect may represent a saturation of risk or a ceiling effect so that in the presence of 
one strong risk factor, a second strong risk factor (perhaps one that works along 
overlapping pathways) doesn’t have room to further increase the risk. 
 
Figure 6: Hazard ratio of major amputation and 95% confidence interval for diabetics on 
insulin or on diet/oral medications only compared to non-diabetics undergoing elective 
procedures and adjusted for smoking interaction.  
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Preoperative smoking status was found to have significant interactions with time 
from index surgery, diabetes and age. We will calculate hazard ratios for major 
amputation by smoking status at 1 year after surgery for 65 year old patients (mean age 
rounded to nearest 5) and stratified by diabetes. As shown in figure 7, current and prior 
smoking status significantly increases risk of major amputation for non-diabetics with 
hazard ratios of 2.10 (95% CI 1.50 - 2.93) and 1.42 (95% CI 1.02 - 1.96) respectively, 
while there is not a significant increase in risk for either level of smoking in the diabetics 
on diet/oral medications and diabetics on insulin.  
 
Figure 7: Hazard ratio for major amputation and 95% confidence interval for current and 
prior smokers compared to never smokers at age 65 and one year after index procedure 
and adjusted for interaction with diabetes. 
 
Race was found to have a significant interaction with ambulatory status before 
index procedure. Hazard ratios of major amputation by race are calculated for ambulatory 
and non-ambulatory patients with white race as the reference level. As shown in figure 8, 
28 
black or other non-white race significantly increases the risk of major amputation in 
ambulatory patients with respective hazard ratios of 1.60 (1.39 - 1.85) and 1.62 (1.36 - 
1.92)  while in non-ambulatory patients there is no significant difference in risk by race.  
 
Figure 8: Hazard ratio for major amputation and 95% confidence interval for black and 
other race compared to white (non-Hispanic) race and adjusted for ambulatory status.  
 
Degree of ischemia was found to have a significant interaction with time from 
procedure and whether or not the index procedure was elective. Hazard ratios for major 
amputation by ischemic status on presentation are calculated for elective versus 
urgent/emergent surgery at 1 year from procedure. As shown in figure 9, presence of 
tissue loss or rest pain significantly increases the risk of major amputation in patients 
undergoing elective surgery compared to those without symptoms of CLTI with 
respective hazard ratios of 2.30 (95% CI 1.79 - 2.96) and 1.76 (95% CI 1.35) but this 
effect is lost in patients undergoing urgent or emergent surgery.  
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Figure 9: Hazard ratio of major amputation and 95% confidence intervals for presentation 
with tissue loss or rest pain compared to presentation without chronic limb threatening 
ischemia (CLTI) and adjusted for whether the index surgery was elective.  
 
Across diabetes, smoking status, race and ischemia we note a common pattern of 
a decrease in the potency of the risk factor in the presence of another specific risk factor.  
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DISCUSSION 
In the absence of an appropriately designed randomized clinical trial it is difficult 
to directly compare different therapeutic approaches, especially when a novel alternative 
is to be compared to a well-established treatment. It can be difficult to even design such a 
trial because of the ethical implications of randomizing patients to a potentially inferior 
therapy. Many options exist to leverage large cross-sectional datasets and statistically 
minimize the bias introduced by the lack of randomization in order to estimate the effects 
of different treatments but this approach requires that information on the therapeutic 
options to be compared exist in such a dataset. Large prospective databases might have 
adequate numbers but lack information on novel treatment options while smaller case 
series and clinical trials which include newer therapeutic approaches lack the numbers for 
higher level model fitting. This project represents a strategy to combine the strength in 
numbers in VQI database with the data on the alternative therapy administered in the 
MOBILE trial to compare distal bypass surgery with the MarrowStim autologous cell 
product using a model to account for baseline differences in risk factors between the 
groups. While powerful in its potential to provide at least a preliminary indication of 
relative efficacy, there are also a number of limitations inherent to both the data and this 
analytic approach. 
The VQI Infra-Inguinal Bypass registry included information on tens of thousands 
of bypass procedures but as with any prospectively collected database there are a 
significant number of missing data points, likely to due to a combination of failure to 
capture, failure to record and loss to follow up. Specifically, amputation status was 
missing on 27% of patients. While the Social Security Death Index (SSDI) provides a 
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mechanism for capturing the majority of mortality, amputation status was only assessed 
during follow up interactions and thus was more sensitive to both attrition and early 
mortality since a patient whose death is noted at 6 months in the Social Security Death 
Index is significantly less likely to receive their 12 month follow up phone call. For this 
reason, a combined end-point of death or amputation was not considered as any inference 
that included mortality but censored the patients with missing amputation status would be 
significantly biased. 
Another aspect of the VQI data is the clustering created by the different 
participating centers. Statistical approaches which account for clustering were used where 
available but the Gray’s test used to compare groups within strata in the non-parametric 
analysis of outcomes after distal bypass with prosthetic conduit does not account for 
clustering in the data. An alternative approach was recently proposed which does not 
assume within cluster independence using a nonparametric cluster bootstrap and might be 
included in any future work with clustered data instead of Gray’s test.25 
In the second portion of the analysis, a potentially significant source of bias 
comes with pooling data from different sources. While the variables considered in model 
selection were collected for both groups, variation in the methods of collection is 
probable and unmeasured cofounders almost certainly exist. For example, patients who 
participate in clinical trials might be expected to have more follow-up visits and closer 
scrutiny compared to those who receive routine post-operative care. 
Additionally, there are the problems inherent in the small sample size of the 
MOBILE trial. With overall just 155 limbs enrolled, covariate estimates will be almost 
entirely driven by the 17,000 patients in the VQI (except for the levels of treatment 
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unique to the MOBILE group). This is expected since the power contributed by the larger 
dataset was the purpose behind the selection of this analytic approach but it does assume 
that the effect of a given covariate estimated from the VQI data is not significantly 
different from that which would be obtained if we had a similar number of MOBILE 
patients (e.g. that the effect of prior bypass on risk of major amputation is similar in the 
VQI and MOBILE patients).  
And finally, because of the 3:1 randomization scheme in the MOBILE trial there 
are just 33 patients in the best medical management group. The consequent and expected 
imprecise estimates of effect in this group as reflected by the wide confidence intervals is 
the reason that this otherwise obvious choice for a control group was not used.  
In the non-parametric analysis of the VQI data, the estimated cumulative 
incidence of major amputation following distal bypass was found to be highest in patients 
who had a non-autologous biologic conduit so this cohort was selected as a reference 
group. Risk of major amputation is lowest in those who had a GSV bypass and prosthetic 
conduit fell between the two. These difference cannot entirely be attributed to the conduit 
type however because of the unequal distribution of risk factors across these groups as 
outlined in table 1 but these findings are nevertheless a reflection of actual outcomes of 
distal bypass by conduit as they are performed across the centers participating in VQI in 
the last decade. This supports the use of GSV first whenever possible and strongly 
suggests that second choice for distal bypass should be prosthetic, although individual 
factors such as infection risk must still be considered; the high estimated incidence of 
amputation in the biologic group at one year may prompt careful consideration of 
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concomitant risk factors and frank discussions with patients regarding their expectations 
for surgery and the option of early amputation. 
The stratification by some common risk factors for the prosthetic cohort was 
provided to inform similar consideration for those patients who are candidates for distal 
bypass without adequate GSV. Specifically, such bypasses with a tibial vessel for outflow 
or in patients who are not ambulatory have an estimated risk of major amputation greater 
than 20% at one year. These estimations of risk should not be applied indiscriminately to 
individual patients as they include the contribution of the spectrum of risk factors found 
in vascular patients and actual risk may be higher or lower for any individual. But they do 
reflect the cumulative incidence across almost four thousand procedures and reflect the 
average risk in that population. The level of risk which is acceptable in any specific case 
remains a shared decision between surgeon and patient.  
Further, while we considered the three main conduit types, not all distal 
reconstruction options were considered in this analysis including the role of heparin 
bonding or vein cuffs (which were included in the prosthetic cohort) or composite or non-
GSV autologous vein options (which were excluded) and remain to be addressed in a 
future study.  
The treatment option which was compared to those three main conduit types in 
this project was autologous cell therapy with MarrowStim, which is composed of never 
frozen and minimally processed nucleated bone marrow cells from the individual patient 
and which was administered to 119 limbs as a part of the MOBILE trial. A cox 
proportional hazards model was fit as described above to identify and account for the role 
of significant risk factors on the incidence of major amputation and estimate the effect of 
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treatment with either distal bypass with GSV or prosthetic or administration of 
MarrowStim or best medical management compared to bypass with non-autologous 
biologic conduit. This approach resulted in findings consistent with what is already 
known about risk factors for amputation including severity of ischemia on presentation, 
age, race, diabetes, ambulatory status, urgency of revascularization procedure and 
smoking history. Treatment was also significant and was notably found to interact with 
age of the patient. The hazard ratios estimated for distal bypass with GSV or prosthetic 
compared to biologic were relatively constant with increasing age so this association 
appears to be largely driven by the MarrowStim therapy which was estimated to 
significantly decrease the risk of major amputation in younger patients (age groups 55 
and 60) compared to both biologic and prosthetic bypass, was still significant compared 
to biologic at 65 years old but lost efficacy compared to either in older patients (age 
group 70). This decrease in benefit with increasing age may be attributed to either 
recipient or donor specific factors. Although these are one and the same in this case, 
recipient factors are related to the body’s ability to respond to cell therapy which is 
thought to be mediated by recruitment and enhancement of pathways related to 
angiogenesis, mitigation of oxidative stress and mitochondrial function, pathways that 
may be less responsive and functional in older patients. Donor factors include the issues 
related to extracting the cell product from older bone marrow which might be expected to 
contain more senescent cell lines and decreased expression of proliferative factors.  
Overall, these findings will inform the design of the MOBILE trial’s successor 
which may include less rigorous exclusion criteria to include not just no option patients 
but those with suboptimal options such as distal bypass with cadaveric vein or artery. The 
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use of an allogeneic cell product from a young health donor may also be considered 
rather than autologous cells, decreasing the procedural burden on the patient. 
Finally, while all the primary aims of the project have been addressed, there 
remains the finding related to the significant interactions between risk factors, notably the 
mitigation of a strong risk factor in the presence of a second risk factor. The significance 
of insulin-dependent diabetes vanished in the presence of current smoking and vice versa. 
The risk associated with non-white race is noted in ambulatory patients but not in the 
non-ambulatory and the increasing risk of amputation with worsening ischemia on 
presentation is only noted for elective surgeries, not for those classified as 
urgent/emergent (although for the latter the definition may be called into question as 
there were a surprising number of patients without CLTI that fell in that category). 
Regardless, this finding is interesting and we suggest that implication of a 
mitigating effect would be misleading. Rather, this may represent evidence for a 
saturation of risk or for a common pathway. For example, diabetes was found to interact 
with smoking status but did not significantly interact with race. This may be because 
current smoking and insulin-dependent diabetes are both stronger risk factors than black 
or other non-white race, so in combination encounter a theoretical “ceiling” of risk sooner 
than the combination of insulin dependent diabetes with black race. This interpretation 
would suggest that all risk factors interact to some extent, including race with diabetes. 
There may be some truth to this as even though that interaction did not reach significance 
at a level of 0.05 with a p-value 0.06154, it was close. 
An alternate though not mutually exclusive interpretation would be a common 
pathway; that is that the downstream physiologic mechanism (e.g. endothelial 
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dysfunction) by which insulin dependent diabetes increases the risk of amputation 
overlaps with that of current smoking so that if the pathway is already fully engaged there 
can be no additional activation by the other risk factor. This is supported by the distinct 
clusters of interactions among the risk factors, suggestive of multiple unique pathways of 
effect. 
Overall, the project has opened several avenues of further investigation. A more 
exhaustive analysis of outcomes by conduit might include composite and non-GSV 
autologous vein conduits as well as a common modification of prosthetic bypass the 
addition of a vein cuff. Specifically, the addition of above the knee bypasses to the cohort 
and an investigation of the contribution of target vessel is indicated as the classic cutoff 
of below versus above the knee may be both too restrictive and too simplistic. This less 
exclusive dataset could also be used to determine if the previously noted interactions 
remain significant with additional observations and judicious non-parametric 
stratification could be used to determine if there is also indication of such interactions 






Figure S-1: Hazard ratio of major amputation and 95% confidence interval for each 
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 Indiana University degree earned at IUPUI   08/19 – 03/2021 
MS Biostatistics 
 
 Washington University School of Medicine in St Louis 08/12 – 05/2016 
Doctor of Medicine 
 
 Montana State University     09/2008 – 05/2012 
Bachelor of Science, College of Letters & Science 
Major:  Cell Biology and Neuroscience 
Minor: German Language Studies 
 
 Eberhard Karls Universität Tübingen    09/2009 – 07/2010 
One year study abroad through Montana State University,  
classes taken in the university medicine program 
 
Academic Honors:   
 Exemplar of Professionalism Honor Roll     04/2019 
Indiana University School of Medicine, 2018-2019 Awardee  
 
 Alpha Omega Alpha (Member of AOA)    08/2015 
medical student inductee 
Washington University School of Medicine,  
 
 Top Third of Class of 2016      08/2015 
Washington University School of Medicine 
 
 
 McGraw-Hill/Lange Medical Student Award   10/2014 
Washington University School of Medicine 
Recognizing academic achievement in the 2013-2014 academic year 
 
 The Edmund V. Cowdry Prize in Histology    10/2013 
Washington University School of Medicine 
Recognizing academic achievement in 1st year histology course 
 
 The Doctor James L. O’Leary Neuroscience Prize   10/2013 
Washington University School of Medicine 
Recognizing academic achievement in the 1st year neuroscience course 
 
 Montana State University Graduation Honors:   05/2012 
Institutional Honors: Highest Honors 
Departmental Honors: University Honors Program - Honors Baccalaureate, 
Summa Cum Laude 
 
 Montana State University's President's Honor Roll   09/2008 – 05/2012 
Recognizing students with 4.0 GPA 
Awarded every semester  
  
Publications/Posters:  
 Abstract        06/2020 
Poster at Society for Vascular Surgery 2020 Annual Meeting (online) 
Allogeneic mesenchymal stromal cells promote muscle fiber regeneration in a 
diabetic mouse model of critical limb ischemia 
Justin R. King, Katherin Leckie, Amy Y. Sato, Teresita M. Bellido, Marlee 
Yancey, Leni Moldovan, Michael P. Murphy, Steven J. Miller 
 
 Abstract        05/2020 
Top abstract at the 4th Annual Riley Hospital Surgical Research Day 
 
Pre-Hospital   High   Volume   Crystalloid Resuscitation   Increases   Mortality   
in Pediatric Traumatic Brain Injury Patients 
Brian Hosfield  MD,  Katherin  Leckie  MD, Cody  Jones  BA,  Alyson  Baker  
MD,  Jodi Raymond MPH, Courtney Rowan MD, Laurie Ackerman  MD,  
Matthew  Landman  MD, MPH, FACS, FAAP 
 
 Book section        05/2020 
Chronic Venous Disease  
In Venous Disease in Mulholland and Greenfield's Surgery: Scientific Principles 
& Practice, 7th edition, edited by Justin B. Dimick, Gilbert R. Upchurch, Jr, 
Hasan B. Alam, Timothy M. Pawlik, Mary Hawn, and Julie Ann Sosa 
Katherin E Leckie, Michael C. Dalsing 
 
 Journal article        02/2020 
Deletion of Socs3 expression in aortic smooth muscle cells ameliorates aortic 
dissection 
JACC: Basic to Translational Research 
Michael Murphy, Justin King, Katherin Leckie 
 
 Abstract        03/2019 
Presentation at Midwestern 2019 
Allogeneic Mesenchymal Stem Cells Induce Regulatory T-Cells and Suppress 
Aneurysm Inflammation: Interim Results of the Phase I ARREST Trial 
Katherin Leckie, Linden L. Green, Justin R. King, Keisin S. Wang, MD, Raghu L. 
Motaganahalli, Andres Fajardo, Michael P. Murphy, John G. Maijub 
 
 Abstract        03/2019 
Presentation at Midwestern 2019 (presented by Justin King) 
The MicroRna Cluster of Mir-15a,-27a,and-92a Are Associated with Diminished 
Il-10 Levels and Decreased Frequency and Immune Suppressor Function of Type-
1 Regulatory T Cells in Patients with Abdominal Aortic Aneurysms 
 
Justin R. King, MD, Linden A. Green, Katherin Leckie, Keisin S. Wang, Praveen 
Kusumanchi, John G. Maijub, Andres Fajardo, Raghu L. Motaganahalli, Michael 
P. Murphy 
 
 Abstract        01/2019 
Plenary presentation at SVS VAM 2019 
Medium Term Effect of Intramuscular Injection of Autologous Bone Marrow 
Cells in Patients with Critical Limb Ischemia: Two Year Follow Up of the 
MOBILE Randomized Clinical Trial 
Katherin E. Leckie, Linden A. Green, Keisin S. Wang, Ashley R. Gutwein, Raghu 
L. Motaganahalli, Andres Fajardo, John G. Maijub, Michael P. Murphy 
 
 Abstract        06/2018 
Poster at SVS VAM 2018 (presented by Justin King) 
Use of Hyperspectral Imaging for Evaluation of Lower Extremity Arterial 
Insufficiency Compared to Ankle-Brachial or Toe-Brachial Indices 
Justin R. King, Katherin Leckie, David Rollins, Lavaraj Timsina, Aaron Franke, 
Christa Dixon, Lynda Nelson, Raghu L. Motaganahalli, MD 
 
 Book Chapter        03/2018 
Open Surgical Reconstruction for Venous Occlusion and Valvular Incompetence 
in Vascular Surgery 
In Current Concepts and Treatments for Venous Disease, An Issue of Surgical 
Clinics, Volume 98-2 edited by Dr. Marc Passman 
Katherin E. Leckie, Michael C. Dalsing 
 
 Poster         10/2011 
Montana State University Student Research Celebration 
Site-directed mutagenesis of R731 of Pyruvate Formate-Lyase and D16 of 
Pyruvate Formate-Lyase Activating Enzyme 
Katherin E Leckie 
 
Other Experience:  
 Indiana University School of Medicine   6/23/16 – Present 
Vascular Surgery Residency – In Progress 
 
 Dedicated research years     07/2018 – 06/2020 
Two years of dedicated research time between clinical years 2 and 3 – in progress 
Focus on mouse models of vascular disease – peripheral arterial disease and 
abdominal aortic aneurysm – and investigation of immunomodulatory therapies. 
 
 Study Abroad in Germany     09/2009 – 07/2010 
Tübingen, Germany 
Description: Year studying abroad in Germany at the Eberhard Karls Universität 
Tübingen, all classes taken in German. 
